|
Aug 14
|
Stoke Therapeutics Second Quarter 2025 Earnings: Beats Expectations
|
|
Aug 13
|
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ...
|
|
Aug 12
|
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 12
|
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
|
|
Aug 12
|
First patient dosed in Phase III trial of zorevunersen for Dravet syndrome
|
|
Aug 11
|
Biogen, Stoke Therapeutics Dose First Patient in Phase 3 Trial of Zorevunersen for Dravet Syndrome
|
|
Aug 11
|
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
|
|
Aug 11
|
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
|
|
Aug 7
|
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates
|
|
Jul 21
|
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome
|
|
Jul 18
|
Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug
|
|
Jul 16
|
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
May 1
|
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
|
May 1
|
Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat?
|
|
Feb 26
|
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
|